Recombinant methionyl human leptin (metreleptin) therapy was shown to improve hyperglycemia, dyslipidemia 44 and insulin sensitivity in patients with lipodystrophic syndromes, but its effects on insulin secretion remain 45 controversial.
baseline and after one-year metreleptin therapy, in 16 consecutive patients with lipodystrophy, diabetes and 48 leptin deficiency.
49
Patients, aged 39.2 ± 4 years (mean ± SEM), presented with familial partial lipodystrophies (n=11, 10 women) 50 or congenital generalized lipodystrophy (n=5, 4 women). Their BMI (23.9 ± 0.7 kg/m 2 ), HbA1c (8.5 ± 0.4%) 51 and serum triglycerides (4.6 ± 0.9 mmol/l) significantly decreased within 1 month of metreleptin therapy, then 52 remained stable. Insulin sensitivity (from hyperglycaemic or euglycemic hyperinsulinemic clamps, n = 4 and 12, 53 respectively), insulin secretion during graded glucose infusion (n=12), and acute insulin response to intravenous 54 glucose adjusted to insulin sensitivity (disposition index, n=12), significantly increased after 1 year of 55 metreleptin therapy. Increase in disposition index was related to decrease in percent total and trunk body fat.
56
Metreleptin therapy improves not only insulin sensitivity, but also insulin secretion in patients with diabetes due 57 to genetic lipodystrophies.
58

INTRODUCTION
Leptin deficiency, linked to reduced fat amount, is thought to importantly contribute to the metabolic 61 complications associated with lipodystrophic syndromes, as shown by studies in mice [1, 2] and humans [3, 4] . In 62 generalized forms of lipodystrophies, metreleptin therapy dramatically decreased liver and muscle lipid content, 63 improving insulin sensitivity, hyperglycemia and dyslipidemia, partly independently of decreased caloric intake 64 [3, 4] . However, in partial forms of lipodystrophies, the effect of metreleptin on hyperglycemia has not been 65 clearly established in patients with moderate baseline metabolic alterations [5] [6] [7] . In addition, the effect of 66 metreleptin on insulin secretion, which remains controversial, has been previously investigated using only oral 67 glucose tolerance tests [3, 6, [8] [9] [10] ].
68
In this study, we evaluated the effect of metreleptin on insulin sensitivity and insulin secretion using dynamic 
81
Recombinant human methionyl-leptin (r-metHuLeptin/metreleptin, Amylin/Bristol-Myers-Squibb/AstraZeneca 82 Pharmaceuticals, San Diego, CA), self-administered in one daily subcutaneous injection at the initial dose of 83 0.02 mg/kg (M0) increased to 0.08 mg/kg at one month (M1), was added to the patients' regimen, stable for at 84 least 6 weeks. Every three months, metreleptin and other medications were adapted to tolerance and 85 effectiveness, and anthropometric parameters, lipid profile, HbA1c, renal and liver function tests were collected.
86
The mean metreleptin daily dose at one year (M12) was 0.10 mg/kg ± 0.02 (SEM).
The first four patients (1 to 4) were evaluated with hyperglycemic clamps, and the twelve subsequent patients (5 90 to 16) with euglycemic hyperinsulinemic clamps and intravenous glucose tolerance test (IVGTT) followed by a 91 graded IV-glucose infusion (glucose ramping).
92
Hyperglycemic clamps allowed the measurement of acute insulin response to an intravenous bolus of glucose 93 (AIR), and the ratio of the glucose disposal rate to insulin concentration (M/I) at the 200 mg/dl-hyperglycemic 94 plateau, as an estimate of insulin sensitivity.
95
Euglycemic hyperinsulinemic clamps estimated the whole-body insulin sensitivity to glucose, expressed as the 
103
A favorable effect of metreleptin on glucose control was defined as a 0.5-point decrease in HbA1c, or HbA1c 104 stability with a decrease of more than 50% in total daily insulin or oral antidiabetic doses, or discontinuation of 105 one antidiabetic class, between M0 and M12. Results are presented as mean ± SEM, unless otherwise specified.
106
See File S1 for supplemental methods and references. 107 108 109
RESULTS
110
Anthropometric and metabolic markers
111
Patients with diabetes, attributable to familial partial lipodystrophy (FPLD) linked to LMNA (nine women), 112 PPARG (one man) or PLIN1 mutations (one woman), or to congenital generalized lipodystrophy attributable to 113 AGPAT2 mutations (CGL1) (four women, one man) were included in the study (Table S1 ). They presented 114 different forms of lipodystrophic syndromes with insulin resistance and dyslipidemia, attributable to already 115 described causative mutations (for review, see [12] ). Their age and BMI were 39.2 ± 4.0 years and 23.9 ± 0.7 116 kg/m 2 , respectively. Their serum leptin was low (2.7 ± 0.5 ng/ml), related to fat mass (r 2 =0.7, p=0.003). BMI, 117 total energy intake (but not food macronutrient distribution), HbA1c, triglycerides, aspartate aminotransferase 118 (AST) and gamma glutamyl transferase levels significantly decreased within the first month of metreleptin therapy, then were not significantly modified until M12 (Table 1 , Figure S1 , and data not shown). After one-year metreleptin therapy, proportion of total body fat and lean masses were not significantly modified, but abdominal 121 and percentage of truncal fat decreased or tended to decrease. Patients used a lower number of antidiabetic 122 classes, and three among nine of them stopped insulin therapy ( Table 1) . One-year changes in BMI, HbA1c and 123 triglycerides were not significantly related to baseline leptin levels.
124
Fourteen of 16 patients met the criteria for a glucose response to metreleptin. However, one of these fourteen 125 patients cannot be formally considered as a responder since, although her glucose control was strikingly 126 improved after one-year metreleptin whereas glitazones were stopped, her basal insulin doses were increased 127 from 24 to 30 U/day and her metformin dose from 1g to 3g per day (patient 9, Table S2 ). The two non-responder 128 patients were the only patient with a PLIN1-linked partial lipodystrophy, and a patient with FPLD2 with 129 moderately elevated baseline HbA1c (patients 6 and 12, Table S2 ). None of them reported any difficulties 130 regarding the compliance with the treatment. Compared to other patients with partial lipodystrophies, they had 131 baseline values of serum leptin, percent body fat, waist circumference and duration of diabetes above the median 132 levels. They were the only patients who did not lose, or even gained weight (+0 and +3.2 kg, respectively) over 133 the one-year period.
134
Insulin sensitivity 135 Insulin-stimulated glucose disposal rate during euglycaemic hyperinsulinemic clamp (n=12) significantly 136 increased during metreleptin therapy, from 2.72 ± 0.79 to 5.44 ± 1.19 mg/kg of fat free mass/min (p=0.0005) for 137 M-value and 0.013 ± 0.005 to 0.031 ± 0.008 mg/kg of fat free mass/min/pmol/l for M/I (p=0.02), showing that 138 the whole-body insulin sensitivity improved. Of note, in three patients (patients 6, 8 and 13, Table S1), 139 euglycemia was maintained without any glucose infusion during the hyperinsulinemic clamp at baseline, while a 140 significant glucose infusion rate was mandatory after one year-metreleptin therapy, pointing to a significant 141 improvement in insulin sensitivity. In the four patients evaluated with the hyperglycemic clamp, M/I increased 142 by a mean of 48% (Table S3 ).
143
Insulin secretion
144
Acute insulin response to intravenous glucose (AIR, n=16) did not significantly increased after one-year 145 metreleptin therapy (88.9 ± 27.5 pmol/kg/min at M0 and 128.8 ± 36.4 at M12, p=0.19). However, insulin 146 secretion rate (ISR) during glucose ramping was higher at every hyperglycemic step (ANOVA overall effect p<0.0001), and the disposition index (AIR x M-value), which adjusts the acute beta-cell function to insulin 148 sensitivity [11] increased after one-year metreleptin (n=12) ( Figure 1 ) (Table S3 ). The AIR x M/I index, assessed 149 in the whole group, also significantly increased (from 6.3 ± 3.8 to 9.2 ± 3.1, p=0.02).
150
Although one-year changes in HbA1c, triglycerides, M-value, and AIR were not significantly associated with 151 modifications in anthropometric parameters (data not shown), disposition index variation was significantly 152 related to changes in percent total body fat (r 2 =0.71, p=0.008), and percent trunk fat mass (r 2 =0.40, p=0.05).
154
Metreleptin response in the LMNA-mutated subgroup of patients
155
In patients with LMNA mutations (n=9), BMI, HbA1c, triglycerides and liver enzymes significantly decreased 156 after one-year metreleptin therapy (data not shown), while M-value increased from 2.88 ± 1.13 to 6.85 ± 1.65 157 mg/kg of fat free mass/min (n=7, p=0.02). ISR increased or tended to increase at the four steps of glucose 158 ramping, with a mean increase of 36%, and the disposition index significantly increased, from 208.8 ± 154.3 to 159 1068 ± 543.9 (n=7, p=0.02) ( Figure S2 and Table S3 ). In this group, the decrease of HbA1c at M12 was 160 positively correlated with the initial HbA1c level (r 2 =0.7, p=0.03), but was not related to the initial leptinemia. 
168
The present study, which used dynamic i.v. clamp techniques in 16 patients with diabetes and endogenous 169 hypoleptinemia due to genetically-determined lipodystrophic syndromes, shows that metreleptin treatment for 1 170 year significantly improved insulin secretion. It also confirms that it decreased HbA1c, triglycerides and liver 171 enzymes and enhanced insulin sensitivity, with a two-fold increase in insulin-stimulated glucose disposal rate 172 after one year, as reported [8] . Importantly, in this context of severe insulin resistance, we adjusted insulin 173 secretion measurements for insulin sensitivity using the disposition index, based on the hyperbolic function 174 linking acute insulin response and insulin sensitivity [11] . Improvement of this index showed that, in patients 175 with lipodystrophy, metreleptin therapy increased beta-cell sensitivity to glucose. that improvement in beta-cell secretory function could result from decreased lipotoxicity. In accordance, the two 178 non-responder patients did not lose, or even gained weight under metreleptin. Leptin could also inhibit glucagon 179 oversecretion, which was reported in insulin-deficient mice [16] and remains to be investigated in patients with 180 lipodystrophy under metreleptin therapy.
181
In patients with partial forms of lipodystrophies as a result of mutations in the LMNA gene, defects of insulin 182 secretion have been suspected to prevent the beneficial effect of metreleptin on glucose homeostasis [5] . Our 183 present results show that metreleptin therapy also increases insulin secretion in this subgroup of patients, 223 Table S1 . Baseline characteristics of the 16 studied patients.
224 Table S2 . Use of antidiabetic medications during metreleptin therapy.
225 Table S3 . Insulin secretion and insulin sensitivity indexes before and one year after metreleptin therapy. M0: baseline, M12: after 12 months of metreleptin therapy; * p<0.05 versus M0 Lean mass (% of total body mass, DEXA)
Energy intake
Total food intake (Kcal/day) The values of LDL-cholesterol were determined from total cholesterol, triglycerides and HDL-cholesterol levels using the Friedewald formula (LDL-cholesterol = total cholesterol minus HDL-cholesterol minus triglycerides (mg/dl) /5), when triglycerides levels were below 400 mg/dl (n=9 patients).
Metabolic, renal and liver parameters
Evaluation of body composition
Total fat and lean masses, and body fat segmental distribution, were measured by dual energy x-ray absorptiometry (DEXA), and abdominal subcutaneous and visceral adipose tissue surfaces (SAT and VAT) were calculated from 1 cm-reconstructed CT-scan slices at the L4 level as previously described [1] .
Caloric and macronutrient intakes were evaluated by three-day food records performed at M0 and M12.
Metabolic investigations
Metabolic investigations were performed after a 12h-overnight fast at M0 and M12. When fasting glycemia was above 7 mmol/l, a 2h-insulin infusion was performed before the investigations. Intravenous glucose tolerance tests (IVGTT, n=16), hyperglycemic and euglycemic hyperinsulinemic clamps (n= 4 and 12, respectively), and graded glucose infusion tests (glucose ramping, n=12) were performed as previously described [2] [3] [4] [5] [6] .
Acute insulin response to an intravenous bolus of glucose (AIR) (n=16 patients)
In 
Hyperglycemic clamp (patients 1 to 4)
Following the intravenous bolus of glucose for the AIR determination, we maintained plasma glucose at 200 mg/dl for 180 min by infusing 20% glucose at varying rates according to blood glucose measurements reformed at 5min-intervals. Blood samples were collected at 160 th , 170 th and 180 th min for the measurement of plasma insulin and C peptide concentrations. We calculated the glucose disposal rate from the glucose infusion rate during the last 20 min of the hyperglycemic plateau after accounting for inter-individual differences in glucose space [3] (in mg/kg body fat-free mass/min). Glucose space correction was calculated as (G 2 -G 1 ) x 0.095 with G 2 and G 1 being the glucose concentrations in mg/dl at the end and at the beginning of each 5-min period during the last 20 min of the clamp. The ratio of the glucose disposal rate to insulin concentration at the 200 mg/dl-hyperglycemic plateau (M/I) was used as an estimate of insulin sensitivity.
Euglycemic hyperinsulinemic clamp (patients 5 to 16)
The insulin-stimulated glucose disposal rate (M-value) was measured during a 100 min-step of 80 mU/m 2 /min insulin infusion, while blood glucose was clamped at 100 mg/dl using variable infusion of 20%
glucose. Blood samples were collected before the clamp and every 10 min during the last 20 min, for the measurement of plasma glucose and insulin. The M-value was calculated according to DeFronzo et al. [3] , after accounting for inter-individual differences in glucose space, and was expressed in mg/kg of fat-free mass/min, using the formula described above. We also calculated the M/I ratio, which adjusted the M-value to the mean insulin concentration during the last 20 min of the test.
Glucose ramping (graded glucose infusion test) (patients 5 to 16)
This test consisted of four consecutive 40-min intravenous infusion of 4, 8, 10 and 12 mg/kg/min of glucose as previously described [2, 4] . Blood samples were collected every 10 minutes during the whole procedure (200 min). The insulin secretion rates (ISR), which evaluate the beta-cell sensitivity to glucose, were assessed from the changes in C-peptide concentrations and the pre-hepatic insulin secretion rate for each of the four glucose infusion steps. ISR was derived by deconvolution, assuming a two-compartmental model of Cpeptide clearance kinetic, using the ISEC software version 3.4a designed by Hovorka R et al (see [5] for more details). Mean ISR for each glucose infusion step was adjusted to fat-free mass and plotted against the corresponding mean glucose concentration, thereby establishing a dose-response relationship between plasma glucose and insulin secretion rate for each patient.
The disposition index (patients 5 to 16) was calculated as the product of AIR by M-value measured during euglycemic hyperinsulinemic clamps [6] .
Statistical analyses
Statistical analyses were performed using GraphPad PRISM (GraphPad Software, Inc, CA, USA) and Statview M0: baseline, M12: after 12 months of metreleptin therapy; * p<0.05 versus M0
B. HbA1c
